These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 3258882

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis.
    Fujii Y, Lindstrom J.
    J Immunol; 1988 Nov 15; 141(10):3361-9. PubMed ID: 2972772
    [Abstract] [Full Text] [Related]

  • 23. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
    Gomez CM, Richman DP.
    J Immunol; 1985 Jul 15; 135(1):234-41. PubMed ID: 3873489
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH.
    J Exp Med; 1976 Sep 01; 144(3):739-53. PubMed ID: 182897
    [Abstract] [Full Text] [Related]

  • 27. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY, Qiao J, Melms A, Link H.
    Cell Immunol; 1993 Dec 01; 152(2):394-404. PubMed ID: 8258147
    [Abstract] [Full Text] [Related]

  • 28. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H, Lambert EH, Walser-Kuntz DR, Yasukawa Y, McCormick DJ, Lennon VA.
    J Immunol; 1997 Aug 01; 159(3):1570-7. PubMed ID: 9233656
    [Abstract] [Full Text] [Related]

  • 29. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ, Oshima M, Deitiker P.
    Crit Rev Immunol; 2001 Aug 01; 21(1-3):1-27. PubMed ID: 11642597
    [Abstract] [Full Text] [Related]

  • 30. Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein.
    Kawanami S, Mori S.
    Fukuoka Igaku Zasshi; 1994 Apr 01; 85(4):120-7. PubMed ID: 8200609
    [Abstract] [Full Text] [Related]

  • 31. Augmented anti-acetylcholine receptor response following long-term penicillamine administration.
    Bever CT, Dretchen KL, Blake GJ, Chang HW, Penn AS, Asofsky R.
    Ann Neurol; 1984 Jul 01; 16(1):9-13. PubMed ID: 6431900
    [Abstract] [Full Text] [Related]

  • 32. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis.
    Asher O, Kues WA, Witzemann V, Tzartos SJ, Fuchs S, Souroujon MC.
    J Immunol; 1993 Dec 01; 151(11):6442-50. PubMed ID: 8245477
    [Abstract] [Full Text] [Related]

  • 33. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
    Hossann M, Li Z, Shi Y, Kreilinger U, Büttner J, Vogel PD, Yuan J, Wise JG, Trommer WE.
    Protein Expr Purif; 2006 Mar 01; 46(1):73-84. PubMed ID: 16230023
    [Abstract] [Full Text] [Related]

  • 34. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria.
    Gomez CM, Richman DP.
    J Immunol; 1987 Jul 01; 139(1):73-6. PubMed ID: 3035025
    [Abstract] [Full Text] [Related]

  • 35. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS, Adikari SB, Huang YM, Link H, Xiao BG.
    Neurobiol Dis; 2004 Jul 01; 16(2):461-7. PubMed ID: 15193302
    [Abstract] [Full Text] [Related]

  • 36. Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors.
    Christadoss P, Lennon VA, Krco CJ, David CS.
    J Immunol; 1982 Mar 01; 128(3):1141-4. PubMed ID: 6799570
    [Abstract] [Full Text] [Related]

  • 37. Binding of myasthenia gravis antibodies to different acetylcholine receptor preparations.
    Zielinski A, Brenner T, Abramsky O.
    Isr J Med Sci; 1982 Apr 01; 18(4):483-6. PubMed ID: 7085248
    [Abstract] [Full Text] [Related]

  • 38. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JB.
    J Immunol; 1996 Jul 01; 157(1):386-92. PubMed ID: 8683141
    [Abstract] [Full Text] [Related]

  • 39. Cytophilic antibodies in experimental autoimmune myasthenia gravis.
    Martinez RD, Tarrab-Hazdai R, Aharonov A, Fuchs S.
    J Immunol; 1977 Jan 01; 118(1):17-20. PubMed ID: 830746
    [Abstract] [Full Text] [Related]

  • 40. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
    Wang ZY, Qiao J, Link H.
    J Neuroimmunol; 1993 May 01; 44(2):209-14. PubMed ID: 8505410
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.